SP-96

• Description:

  SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM) . SP-96 can be used for the research of triple negative breast cancer (TNBC) [1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H320, H335

• Target:

  Aurora Kinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sp-96.html

• Purity:

  99.65

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=CC=CC(NC2=C3C=CC(C4=CN(C)N=C4)=CC3=NC=N2)=C1)NC5=CC=CC(F)=C5

• Molecular Formula:

  C25H20FN7O

• Molecular Weight:

  453.47

• Precautions:

  H302, H315, H320, H335

• References & Citations:

  [1]Naga Rajiv Lakkaniga, et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Aurora A; Aurora B

• CAS Number:

  [2682114-54-9]